MDD vs. MDR — What Changed?
EU Regulation 2017/745 (MDR) replaced Directive 93/42/EEC (MDD) and Directive 90/385/EEC (AIMDD), representing the most significant overhaul of European medical device regulation in over 25 years. For urology device manufacturers, the MDR introduces heightened clinical evidence standards, expanded technical documentation requirements, mandatory post-market follow-up, and a new device registration system (EUDAMED) that increases transparency across the supply chain.
The transition was phased: Class III and implantable Class IIb devices first, followed by other Class IIb and Class IIa devices. Understanding where your urology portfolio sits in this timeline is the critical first step in your MDR strategy.
| Requirement Area | MDD (93/42/EEC) | MDR (2017/745) |
|---|---|---|
| Classification basis | 18 rules (Annex IX) | 22 rules — stricter reclassification for several device types |
| Clinical data | Clinical evaluation, equivalence accepted broadly | Stricter equivalence criteria; CER mandatory; PMCF required |
| Technical documentation | Essential Requirements (Annex I) | GSPR (Annex I) + full TD per Annex II & III |
| UDI system | Not mandatory (US UDI only) | Mandatory UDI-DI + UDI-PI, EUDAMED registration |
| Notified Body oversight | Periodic audits | Unannounced audits; NB product testing rights |
| Post-market surveillance | PSUR (Class III only) | PSUR (Class IIb+), PMCF plan, vigilance reporting |
| Person Responsible | Not required | Mandatory PRRC (Person Responsible for Regulatory Compliance) |
Key Impact for Urology Manufacturers
Ureteral access sheaths, balloon dilators, nephrostomy tubes, and suction sheaths used in minimally invasive urology procedures are typically classified as Class IIa under MDR Rule 5 (Invasive Devices - Body Orifices) or Rule 6 (Surgically Invasive Devices — Short-term). This classification demands Notified Body involvement, a full Technical Documentation file, and a rigorous Clinical Evaluation Report (CER) with mandatory PMCF.
Classification Changes for Urology Devices
The MDR introduced four new classification rules (Rules 19–22) and significantly revised existing rules. For urology device manufacturers, the key classification rules are:
Invasive Devices with Respect to Body Orifices — Short-term
Invasive devices with respect to body orifices are generallyClass IIa.Ureteral balloon dilators (e.g., for ureteral tract dilation) or Ureteral Access Sheath may fall here.
Surgically Invasive Devices — Short-term
Surgically invasive devices intended for short-term use are generally Class IIa. PCNL balloon dilators used percutaneously (e.g., for nephrostomy tract dilation) may fall here.
NEW: Devices Incorporating Nanomaterials
A new MDR rule with no MDD equivalent. If your device coating or material incorporates nanoscale particles, this rule may apply and can escalate classification significantly. Nitinol-based devices should be reviewed against this rule.
Urology Device Classification Quick Reference
| Device Type | Typical Class | Primary Rule |
|---|---|---|
| Ureteral Access Sheath (UAS) | IIa | Rule 5 |
| High-Pressure Balloon Dilator | IIa | Rule 5 |
| Nephrostomy Balloon Dilator | IIa | Rule 6 |
| Ureteral Catheter / Stent | IIa / IIb | Rule 8 |
| Suction-Assisted UAS | IIa | Rule 5 |
Technical Documentation — Annex II & III
The MDR imposes a substantially expanded Technical Documentation (TD) requirement compared to MDD. Under Annex II and Annex III, manufacturers must maintain a comprehensive, structured TD file that is continuously updated throughout the device lifecycle — not just at the time of CE marking.
Annex II — Technical Documentation
- ✓ Device description & specification
- ✓ Design & manufacturing information
- ✓ GSPR (General Safety & Performance Requirements)
- ✓ Risk/benefit analysis per ISO 14971
- ✓ Product verification & validation
- ✓ Clinical evaluation (CER)
- ✓ PMS documentation
Annex III — PMS Technical Documentation
- ✓ PMS plan (per Annex III, §1)
- ✓ PMCF plan & evaluation report
- ✓ PSUR (Class IIb: annual)
- ✓ Summary of Safety & Clinical Performance (SSCP)
- ✓ Field safety corrective action records
- ✓ Vigilance reports (MDR Article 87)
- ✓ Trend reporting obligations
Live Document Requirement
Unlike MDD, where the Technical File was primarily a point-in-time submission, the MDR requires Technical Documentation to be a living, continuously updated set of records. Any change to design, materials, manufacturing process, labelling, or intended purpose triggers a change management review and potential NB re-evaluation. Quality Management Systems (ISO 13485) must be aligned to enforce this lifecycle management.
UDI & EUDAMED Registration
The Unique Device Identification (UDI) system is a new mandatory requirement under MDR Article 27. Every device placed on the EU market must carry a UDI — a structured numeric or alphanumeric code that enables identification of a specific device model (UDI-DI) and specific production unit (UDI-PI). Manufacturers must also register all devices and operators in EUDAMED, the European database on medical devices.
UDI-DI
Device Identifier — identifies the specific device model/version. Unique to labelling, packaging level, and type.
UDI-PI
Production Identifier — serial number, lot/batch number, manufacture date, expiry date. Identifies individual units.
EUDAMED
EU database where UDI-DI data must be uploaded. Enables traceability and post-market surveillance across the EU.
Issuing Entities Accepted by EU MDR
The MDR designates the following organisations as accredited UDI issuing entities: GS1 (GTIN-based barcodes/2D DataMatrix), HIBCC (Health Industry Business Communications Council), ICCBBA (for cellular and tissue products), and IFA (German pharmaceutical code). For urology devices, GS1 is the most commonly used issuing entity.
UDI carriers (barcodes or 2D DataMatrix codes) must appear on the device label and, for Class IIb devices, also on higher-level packaging.
Clinical Evidence & the CER
MDR Article 61 and Annex XIV establish that every device must have a Clinical Evaluation Report (CER) demonstrating clinical safety and performance based on sufficient clinical evidence. For Class IIb urology devices, this typically means systematic literature review plus clinical data from equivalent devices and/or Post-Market Clinical Follow-up (PMCF) studies.
Scope the Clinical Evaluation Plan (CEP)
Define intended purpose, target patient population, indications, and contraindications. Identify applicable MEDDEV 2.7/1 rev 4 methodology.
Identify Equivalent Device(s)
MDR sets strict equivalence criteria — technical, biological, and clinical similarity must all be demonstrated. Equivalence to a competitor device now requires a contractual data access agreement.
Systematic Literature Review
Search PubMed, Embase, and Cochrane for clinical studies, registry data, and adverse event reports. Appraise quality and relevance using validated assessment tools.
Write Clinical Evaluation Report (CER)
Synthesise all clinical data into the CER, demonstrating that benefits outweigh risks based on current state-of-the-art. The CER must be authored or reviewed by a qualified person.
PMCF Plan & Evaluation Report
Mandatory for Class IIb devices. Define proactive data collection methods (surveys, registry studies, literature surveillance) to continuously validate safety and performance post-CE mark.
GSPR — General Safety & Performance Requirements
Annex I of the MDR contains the General Safety and Performance Requirements (GSPR), which replace the MDD's Essential Requirements. The GSPR is more granular, more prescriptive, and requires explicit, traceable evidence of compliance against every applicable requirement in your Technical Documentation.
GSPR Structure for Urology Devices
Harmonised Standards — Your GSPR Compliance Toolkit
Compliance with applicable harmonised standards (published in the Official Journal of the EU) creates a presumption of conformity with the corresponding GSPR. Key standards for urology devices include: ISO 10993 (biocompatibility), ISO 11135 / ISO 11137 (sterilization), ISO 14971 (risk management), ISO 11607 (sterile packaging), and EN ISO 10555 (intravascular catheters). Maintaining a GSPR checklist with standard references and objective evidence is the recommended approach.
Post-Market Surveillance (PMS & PMCF)
Articles 83–86 of the MDR establish a proactive, systematic post-market surveillance obligation. Unlike the more reactive MDD approach, MDR requires manufacturers to actively collect and analyse post-market data to confirm the safety and performance profile of their devices throughout their commercial lifecycle.
PMS Data Sources
- Customer complaint records
- Published clinical literature
- Competent authority databases (EUDAMED, MAUDE)
- Field safety corrective actions (FSCAs)
- Clinician feedback & KOL surveys
- Registry data
Reporting Outputs (Class IIb)
- PSUR — Periodic Safety Update Report (annual)
- PMCF Evaluation Report (updated at PSUR)
- SSCP — Summary of Safety & Clinical Performance (public)
- Serious incident reports (15-day EUDAMED upload)
- Trend reports when statistical thresholds exceeded
Notified Body Pathway
For Class IIb urology devices, a Notified Body (NB) assessment is mandatory. NBs designated under MDR are published in the NANDO database maintained by the European Commission. As of 2026, the number of MDR-designated NBs has increased from the initial wave, but capacity constraints remain — engaging your NB early is essential.
Conformity Assessment Routes for Class IIb
Manufacturers can follow either Annex IX (QMS audit + technical documentation review) or Annex X + XI (type examination + QMS). For most urology device manufacturers with ISO 13485 certification, Annex IX is the standard pathway. The NB will assess the full Technical Documentation and may request physical product samples for independent testing.
Unannounced Audit Rights
A significant MDR change: NBs now have the right to conduct unannounced factory audits and to select and test samples taken from the market without prior notice. Manufacturing sites must maintain continuous readiness — quality systems, device history records, complaint files, and PMS documentation must be current and accessible at all times.
MDR Transition Timeline
The MDR transition has been extended multiple times due to NB capacity shortfalls. As of 2026, the applicable deadlines under EU Regulation 2023/607 (the "MDR Extension Regulation") are:
PASSED
MDR applies to Class III & Class IIb implantable devices
New devices and those without MDD certificates from this date must follow MDR. Legacy MDD-certified Class III/IIb implantables had extended transitions.
Class IIb non-implantable & Class IIa MDD certificates expire
All Class IIb non-implantable devices (including most urology devices) must have valid MDR certification by this date. This is the critical deadline for most urology manufacturers.
Class I MDD self-declarations expire
Devices that were self-certified under MDD as Class I but require NB assessment under MDR must complete their NB pathway by this date.
Continuous MDR obligations for certified devices
Once MDR-certified, ongoing PMS, PSUR, EUDAMED updates, and NB surveillance activities apply for the entire commercial lifecycle of the device.
Envaste MDR Commitment
Envaste has maintained a proactive MDR compliance programme since 2020. Our Manawa and Tahina product lines are supported by comprehensive Technical Documentation, GSPR matrices, live CERs, and ISO 13485-aligned quality systems. We work with our distribution partners to ensure product availability throughout their market regions remains uninterrupted through regulatory transitions. Contact our Quality & Regulatory team for specific product compliance status.